Clinical Microbiology and Antimicrobial Chemotherapy. 2002; 4(1):61-69
Streptococcus pneumoniae is one of the leading pathogens causing meningitis, otitis media, sinusitis, and community-acquired pneumonia in different age groups. A special problem for the time being is an increase of drug-resistant pneumococci isolated in different nosological forms, which leads to the additional expenses on management of such patients. Together with of effective antimicrobial agents, currently there is a possibility of implementation of specific prophylaxis of pneumococcal infections both in adults and children. Licensed in Russian Federation 23-valent polysaccharide vaccine is effective and safe upon usage in individuals of >2 years of age, but, it provides insufficient protection in children Ј2 years old. However, licensed in 2000 in the USA and some countries of Western Europe conjugated 7-valent vaccine showed efficacy in children of this age group, which give wide prospective for prophylaxis of pneumococcal infections. This review presents current, evidence-based recommendations on usage of pneumococcal vaccines and also perspectives of vaccination.